Search details
1.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
N Engl J Med
; 389(9): 783-794, 2023 Aug 31.
Article
in English
| MEDLINE | ID: mdl-37646676
2.
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Blood
; 137(13): 1818-1827, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33150384
3.
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Haemophilia
; 28(4): 548-556, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35475308
4.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Haemophilia
; 27(6): 911-920, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34614267
5.
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Haemophilia
; 27(6): 921-931, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34636112
6.
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Haemophilia
; 26(4): e168-e178, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32597029
7.
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
Blood
; 128(5): 630-7, 2016 08 04.
Article
in English
| MEDLINE | ID: mdl-27330001
8.
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Blood
; 126(9): 1078-85, 2015 Aug 27.
Article
in English
| MEDLINE | ID: mdl-26157075
9.
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study.
Ther Adv Hematol
; 14: 20406207231178596, 2023.
Article
in English
| MEDLINE | ID: mdl-37465396
10.
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Expert Rev Hematol
; 16(10): 793-801, 2023.
Article
in English
| MEDLINE | ID: mdl-37646148
11.
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
; 10(5): e322-e332, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37003278
12.
Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study.
Res Pract Thromb Haemost
; 6(2): e12665, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35224416
13.
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
J Blood Med
; 12: 483-495, 2021.
Article
in English
| MEDLINE | ID: mdl-34188580
14.
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
Clin Appl Thromb Hemost
; 26: 1076029620950836, 2020.
Article
in English
| MEDLINE | ID: mdl-32866032
15.
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
J Blood Med
; 11: 345-356, 2020.
Article
in English
| MEDLINE | ID: mdl-33117020
16.
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
J Blood Med
; 11: 213-225, 2020.
Article
in English
| MEDLINE | ID: mdl-32607039
17.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Clin Appl Thromb Hemost
; 26: 1076029620946839, 2020.
Article
in English
| MEDLINE | ID: mdl-32816519
18.
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
Blood Coagul Fibrinolysis
; 28(2): 152-162, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27203734
19.
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Thromb Haemost
; 117(9): 1705-1713, 2017 08 30.
Article
in English
| MEDLINE | ID: mdl-28692108
Results
1 -
19
de 19
1
Next >
>>